Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids

Patent metadata

Field	Value
Publication number	US-11732244-B2
Application number	US-202017021163-A
Country	US
Kind code	B2
Filing date	Sep 15, 2020
Priority date	Jan 26, 2012
Publication date	Aug 22, 2023
Grant date	Aug 22, 2023

Abstract

Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

First claim

The invention claimed is:

1. A method of enhancing the infectivity of a human immunodeficiency virus, the method comprising contacting the virus with an alkyne-modified fatty acid or physiologically acceptable salt thereof in an amount effective to enhance the infectivity of the virus, wherein the alkyne-modified fatty acid or physiologically acceptable salt thereof has the formula:
Y—CH 2 —X—CO 2 H

wherein,
Y is an ethynyl group; and
X is a linear carbon chain comprising 8 to 15 carbons; and wherein the alkyne-modified fatty acid is one that is attached to a protein through an intracellular myristoylation or palmitoylation pathway.

2. The method of claim 1 , wherein the virus is in a cell.

3. The method of claim 2 , wherein the cell is a human animal cell or a non-human animal cell.

4. The method of claim 1 , wherein the human immunodeficiency virus is HIV-1.

5. The method of claim 1 , wherein the contacting is performed in a solution comprising at least one of animal serum, amino acids, buffers, fatty acids, glucose, hormones, inorganic salts, lipids, metal ion chelators, peptides, surfactants, trace metals, and vitamins.

6. The method of claim 1 , wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl or 12-ethynyldodecanyl.

7. The method of claim 1 , wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl.

8. The method of claim 1 , wherein the alkyne-modified fatty acid moiety is 12-ethynyldodecanyl.

9. The method of claim 1 , wherein the alkyne-modified fatty acid moiety is attached to the virus by an amide or a thioester bond.

10. The method of claim 1 , wherein the virus is inactivated.

11. The method of claim 1 , wherein the virus is attenuated.

Assignees

• Life Technologies Corp
• Univ Johns Hopkins

Inventors

• Agnew Brian
• Graham David

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2740/16045

  Special targeting system for viral vectors · CPC title